암 바이오마커 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global cancer biomarker market size is expected to reach USD 132.06 Billion in 2034 from USD 43.75 Billion in 2025, growing at a CAGR of 13.06 during 2026-2034.This market is advancing rapidly due to the increasing need for early detection, diagnosis, and personalized treatment of cancer. Cancer biomarkers are biological molecules that indicate the presence or progression of cancer, enabling more accurate and timely interventions. The rising global burden of cancer and the growing emphasis on precision medicine are significantly contributing to market growth. Healthcare systems are increasingly adopting biomarker-based diagnostics to improve patient outcomes.

Key drivers include advancements in molecular biology, increasing investment in oncology research, and the expansion of diagnostic technologies. Biomarkers are widely used in screening, prognosis, and treatment monitoring, enhancing the effectiveness of cancer therapies. The integration of genomics and proteomics is enabling the identification of new biomarkers, further expanding their application. Additionally, the growing adoption of companion diagnostics is supporting market expansion.

Future prospects indicate strong growth potential, with continuous innovation in biomarker discovery and validation. The development of non-invasive diagnostic methods, such as liquid biopsies, will enhance accessibility and patient comfort. Emerging markets are expected to witness increased adoption due to improving healthcare infrastructure. As precision oncology continues to evolve, the cancer biomarker market is poised for sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Biomolecule Type

• Protein
• Genetic Biomarkers

By Cancer Type

• Colorectal Cancer
• Lung Cancer
• Prostate Cancer
• Breast Cancer
• Stomach Cancer
• Throat Cancer
• Others

By Application

• Personalized/Modified Medicine
• Diagnosis
• Novel Drug Research and Development

By Technology

• Bioinformatics and Cytogenetics
• Imaging
• Omics
• Others

COMPANIES PROFILED

• Abbott Laboratories, Biomerieux, Thermo Fisher Scientific, Quest Diagnostics, Dickinson and Company, Roche Diagnostics, Agilent Technologies, Illumina, Qiagen, Affymetrix Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER BIOMARKER MARKET: BY BIOMOLECULE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Biomolecule Type
• 4.2. Protein Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Genetic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER BIOMARKER MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Cancer Type
• 5.2. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Stomach Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Throat Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER BIOMARKER MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Personalized/Modified Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Novel Drug Research and Development Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER BIOMARKER MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Technology
• 7.2. Bioinformatics and Cytogenetics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Imaging Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Omics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CANCER BIOMARKER MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Biomolecule Type
  • 8.2.2 By Cancer Type
  • 8.2.3 By Application
  • 8.2.4 By Technology
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Biomolecule Type
  • 8.3.2 By Cancer Type
  • 8.3.3 By Application
  • 8.3.4 By Technology
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Biomolecule Type
  • 8.4.2 By Cancer Type
  • 8.4.3 By Application
  • 8.4.4 By Technology
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Biomolecule Type
  • 8.5.2 By Cancer Type
  • 8.5.3 By Application
  • 8.5.4 By Technology
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Biomolecule Type
  • 8.6.2 By Cancer Type
  • 8.6.3 By Application
  • 8.6.4 By Technology
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CANCER BIOMARKER INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Abbott Laboratories
  • 10.2.2 Biomerieux
  • 10.2.3 Thermo Fisher Scientific
  • 10.2.4 Quest Diagnostics
  • 10.2.5 Dickinson And Company
  • 10.2.6 Roche Diagnostics
  • 10.2.7 Agilent Technologies
  • 10.2.8 Illumina
  • 10.2.9 Qiagen
  • 10.2.10 Affymetrix Inc